Literature DB >> 18495428

Rate-difference method proved satisfactory in estimating the influenza burden in primary care visits.

Angelique G S C Jansen1, Elisabeth A M Sanders, Jacco Wallinga, Eelke J Groen, Anton M van Loon, Arno W Hoes, Eelko Hak.   

Abstract

OBJECTIVE: To compare different methods to estimate the disease burden of influenza, using influenza and respiratory syncytial virus-(RSV) associated primary care data as an example. STUDY DESIGN AND
SETTING: In a retrospective study in the Netherlands over 1997-2003, primary care attended respiratory episodes and national viral surveillance data were used to compare the rate-difference method to other, more complex methods.
RESULTS: The influenza-associated excess estimated by the different methods varied. The estimates provided by the rate-difference model lay well within this range. According to the rate-difference method, influenza-associated primary care consultations were present for all ages, including low-risk adults. The highest influenza-associated burden was demonstrated for children below the age of 5 years. The RSV-associated primary care burden was highest in the youngest age category and well above that associated with influenza. Significant RSV-associated excess was also recorded among adults, particularly in high-risk adults and the elderly.
CONCLUSION: The straightforward rate-difference model seemed satisfactory to estimate the influenza-associated burden. Significant influenza-associated excess was demonstrated among persons not yet recommended for influenza vaccination in The Netherlands. The RSV-associated burden was highest for the youngest children, but also significant for adults.

Entities:  

Mesh:

Year:  2008        PMID: 18495428     DOI: 10.1016/j.jclinepi.2007.08.017

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign.

Authors:  Carlos G Grijalva; Yuwei Zhu; Lone Simonsen; Marie R Griffin
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

2.  Contribution of respiratory tract infections to child deaths: a data linkage study.

Authors:  Pia Hardelid; Nirupa Dattani; Mario Cortina-Borja; Ruth Gilbert
Journal:  BMC Public Health       Date:  2014-11-20       Impact factor: 3.295

3.  Establishing seasonal and alert influenza thresholds in Morocco.

Authors:  Ahmed Rguig; Imad Cherkaoui; Margaret McCarron; Hicham Oumzil; Soumia Triki; Houria Elmbarki; Abderrahman Bimouhen; Fatima El Falaki; Zakia Regragui; Hassan Ihazmad; Chakib Nejjari; Mohammed Youbi
Journal:  BMC Public Health       Date:  2020-06-29       Impact factor: 3.295

4.  Estimation of influenza- and respiratory syncytial virus-attributable medically attended acute respiratory infections in Germany, 2010/11-2017/18.

Authors:  Matthias An der Heiden; Udo Buchholz; Silke Buda
Journal:  Influenza Other Respir Viruses       Date:  2019-07-24       Impact factor: 4.380

5.  Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.

Authors:  Marina Treskova; Francisco Pozo-Martin; Stefan Scholz; Viktoria Schönfeld; Ole Wichmann; Thomas Harder
Journal:  Pharmacoeconomics       Date:  2021-01-19       Impact factor: 4.981

6.  Estimates of excess medically attended acute respiratory infections in periods of seasonal and pandemic influenza in Germany from 2001/02 to 2010/11.

Authors:  Matthias An der Heiden; Karla Köpke; Silke Buda; Udo Buchholz; Walter Haas
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

7.  The impact of national vaccination policy changes on influenza incidence in the Netherlands.

Authors:  Scott A McDonald; Liselotte van Asten; Wim van der Hoek; Gé A Donker; Jacco Wallinga
Journal:  Influenza Other Respir Viruses       Date:  2016-02-02       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.